Aptose Biosciences Brief: Says Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AML; Adds Tuspetinib "Continues Broad Activity Across Mutations With Excellent Safety Profile"
Aptose Biosciences Brief: Says Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AML; Adds Tuspetinib "Continues Broad Activity Across Mutations With Excellent Safety Profile"
Aptose Biosciences簡介：表示Tuspetinib將在1L AML中進入TUS+VEN+HMA三聯療法試點研究；並補充說，Tuspetinib “在突變中繼續具有廣泛的活性，具有出色的安全性”
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。